key: cord-0898205-id0r3h3f
authors: Voigt, Emily A.; Gerhardt, Alana; Hanson, Derek; Battisti, Peter; Reed, Sierra; Singh, Jasneet; Mohamath, Raodoh; Jennewein, Madeleine F.; Bakken, Julie; Beaver, Samuel; Press, Christopher; Soon-Shiong, Patrick; Paddon, Christopher J.; Fox, Christopher B.; Casper, Corey
title: A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
date: 2022-03-23
journal: bioRxiv
DOI: 10.1101/2022.03.22.485230
sha: b3f2c4c0000cdf24bc1c5c2eaf271f512960a4d4
doc_id: 898205
cord_uid: id0r3h3f

mRNA vaccines were the first to be authorized for use against SARS-CoV-2 and have since demonstrated high efficacy against serious illness and death. However, limitations in these vaccines have been recognized due to their requirement for cold storage, short durability of protection, and lack of access in low-resource regions. We have developed an easily-manufactured, potent self-amplifying RNA (saRNA) vaccine against SARS-CoV-2 that is stable at room temperature. This saRNA vaccine is formulated with a nanostructured lipid carrier (NLC), providing enhanced stability, improved manufacturability, and protection against degradation. In preclinical studies, this saRNA/NLC vaccine induced strong humoral immunity, as demonstrated by high pseudovirus neutralization titers to the Alpha, Beta, and Delta variants of concern and induction of long-lived bone marrow-resident antibody secreting cells. Robust Th1-biased T-cell responses were also observed after prime or homologous prime-boost in mice. Notably, the saRNA/NLC platform demonstrated thermostability at room temperature for at least 6 months when lyophilized. Taken together, this saRNA delivered by NLC represents a potential improvement in RNA technology that could allow wider access to RNA vaccines for the current COVID-19 and future pandemics.

More than 470 million confirmed cases of coronavirus disease 2019 and 6 million related 41 deaths have occurred worldwide due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 42 as of March 2022. 1 Although multiple SARS-CoV-2 vaccines have been developed and over 11 billion 43 SARS-CoV-2 vaccine doses have been administered globally, 1 only 14.4% of people in low-income 44 countries have received a dose. 2 New vaccines that can be manufactured rapidly and stored without 45 complex cold-chain requirements and result in long-term, robust, multi-variant immunity are urgently 46 needed to protect people across the globe against SARS- A room-temperature stable SARS-CoV-2 saRNA vaccine 5 RESULTS 86

Our baseline saRNA/NLC SARS-CoV-2 vaccine candidate (designated D614G) consisted of the codon-88 optimized Wuhan-D614G spike protein sequence 35 ( Figure 1A ). This vaccine saRNA was complexed with 89 an NLC delivery nanoparticle by simple mixing to create the vaccine complex with the RNA bound to the 90 exterior of the NLC nanoparticle ( Figure 1B ) and with an average hydrodynamic particle size of 89 ± 3 nm 91 ( Figure 1C ). Complexing the saRNA with NLC allowed for retention of RNA integrity even in the presence 92 of RNase ( Figure 1D ). The formulated vaccine was then transfected into HEK-293 cells where it 93 demonstrated significant SARS-CoV-2 spike protein expression 24 hours post-transfection as measured 94 by western blot ( Figure 1E ). In order to mitigate supply chain issues for the least readily available 95 ingredient of the NLCs, the cationic lipid DOTAP, we also tested DOTAP from multiple independent 96 manufacturers and demonstrated similar physicochemical properties and 3-month stability of the 97 resulting NLCs, indicating that material to supply large-scale manufacturing may likely be successfully 98 sourced from multiple vendors (Supplementary Table S1 ). 99

To test vaccine immunogenicity of the baseline D614G vaccine candidate, complexed saRNA/NLC was 102 injected intramuscularly into C57BL/6J mice at 1, 10, or 30 µg doses, with a boost dose 3 weeks post-103 prime. As a negative vector control, an saRNA expressing the non-immunogenic reporter secreted 104 embryonic alkaline phosphatase (SEAP) gene in the place of the SARS-CoV-2 spike gene was used at a 10 105 µg dose. Serum samples were taken 21 days post-prime and 21 days post-boost. These samples were 106 assessed for SARS-CoV-2 spike protein-binding IgG, IgG1, and IgG2a antibodies by enzyme-linked 107 6 immunosorbent assay (ELISA) and for SARS-CoV-2 neutralizing antibodies by pseudovirus neutralization 108 assay ( Figure 2) . 109

Strong antibody responses to SARS-CoV-2 spike protein were detected in all vaccinated mice 110 post-prime (Figure 2A) , with a statistically significant but relatively small rise in titers after the boost 111 dose (p = 0.0054). A clear dose-dependency was seen across the mouse groups. Strong neutralization of 112

Wuhan-D614G pseudotyped lentiviral particles was evident in all vaccinated mouse sera post-prime and 113 post-boost ( Figure 2B ), with no detectable neutralization noted in vector control-vaccinated mouse sera. 114

Ratios of IgG2a (Th1) to IgG1 (Th2) antibody titers indicated a robust Th1 bias in the humoral responses 115 to the baseline D614G saRNA/NLC vaccine ( Figure 2C ). 116

We next sought to optimize the SARS-CoV-2 spike protein sequence for the induction of SARS-CoV-2 118 antibodies capable of neutralizing multiple variants of the virus. C57BL/6J mice were injected 119 intramuscularly with 10 µg of saRNA/NLC vaccine expressing the native D614G spike protein sequence, 120 the D614G spike protein sequence with a diproline mutation that stabilized the prefusion conformation 121 of the spike trimer 36, 37 (designated D614G-2P), or the D614G diproline-stabilized spike protein with a 122 QQAQ mutation that ablated the furin cleavage site 38 (designated D614G-2P-3Q). Each saRNA candidate 123 was complexed with NLC in the same manner as with the baseline candidate, and similar vaccine particle 124 size, RNA integrity, and in vitro spike protein expression were observed as in Figure 1 (Supplemental 125 Figure S1 ). Mice were again administered prime and boost injections 3 weeks apart, and serum samples 126 were taken 3 weeks post-prime and 3 weeks post-boost vaccine dose. All vaccine candidates were well 127 tolerated based on mouse general appearance and behavior, with no signs of weight loss or injection 128 site reactogenicity, similar to previous studies with this saRNA/NLC platform. 33, 34, 39, 40 SARS-CoV-2 spike-129 7 binding IgG antibodies were assessed in mouse sera by ELISA, and SARS-CoV-2 variant neutralization was 130 evaluated by pseudovirus neutralization assay ( Figure 3) . 131

All three vaccine candidates induced strong SARS-CoV-2 spike-binding serum IgG titers at high 132 levels post-prime, with a significant increase post-boost ( Figure 3A , average 2.7-fold change post-boost, 133 p = 0.013 across groups). No significant difference in spike-binding IgG titers was seen between the 134 three candidates post-boost (p = 0.7276). The candidates differed only in their ability to consistently 135 induce antibodies in all mice that cross-neutralize emerging SARS-CoV-2 variants ( Figure 3B-D After selecting AAHI-SC2 as lead vaccine candidate, we conducted a vaccine dosing study in mice with 147 comprehensive humoral and cellular immunogenicity characterization. C57BL/6J mice were immunized 148 in prime or prime-boost regimens with AAHI-SC2 at doses of 1, 10, or 30 µg. Serum samples were 149 collected to measure SARS-CoV-2 spike-specific IgG ( Figure 4A ) and neutralizing antibody titers ( Figure  150 4B-C). Bone marrow samples were taken post-boost and used for measurement of SARS-CoV-2 spike-151 specific IgA-and IgG-secreting cells by ELISpot ( Figure 4D -E). 152 8 High levels of SARS-CoV-2 IgG antibodies were induced in mouse sera in a dose-dependent 153 manner, with even a 1 µg dose inducing high responses ( Figure 4A ). Boost vaccine doses increased IgG 154 titers a small but significant degree at all doses (average 3-fold change, p < 0.0001). Sera were able to 155 neutralize Wuhan, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) pseudoviruses at high levels, 156 both after prime-only and prime-boost vaccination ( Figure 4B -C). A significant decrease in the ability of 157 the mouse sera to neutralize the Beta and Delta variants was evident relative to Wuhan strain 158 neutralization as expected both post-prime (average p < 0.0001 and p = 0.0002, respectively) and post-159 boost (p = 0.0006 and p < 0.0001, respectively); however, neutralization of all three variants still 160 generally remained at high, detectable levels. High levels of post-boost bone marrow-resident IgA-161 secreting and IgG-secreting cells were detected ( Figure CoV-2 spike overlapping peptides and stained for a panel of T cell markers and cytokines generated 174 results consistent with the T cell ELISpot findings. High levels of responsive CD4+ Th1 and robust CD8+ T 175 cell populations were stimulated with prime vaccination alone, and these were increased several-fold in 176 9 a dose-dependent manner after boost injection. Polyfunctional, triple-positive IFNγ-, IL-2-, and TNFα-177 secreting CD4+ ( Figure 5C ) and CD8+ T cells ( Figure 5D ) were stimulated at whole-percentage levels after 178 a prime dose alone and remained high post-boost. Large populations of IFNγ+ and TNFα+ cells post-179 prime, increasing to a large degree post-boost, drove a significant SARS-CoV-2-specific significant CD4 180 Th1 response and a large CD8 T cell response ( Figure 5E -F), representing up to 20% of the CD8 cell 181 population in the highest-dosed group. Conversely, the CD4 Th2 response was minimal at all timepoints, 182

generally remaining under 2% of CD4 cells, and only measurable at the highest vaccine doses ( Figure 5E -183 F). 184

Lyophilized AAHI-SC2 vaccine is thermostable, enabling long-term storage 185

Short-term stability of the liquid AAHI-SC2 vaccine in an excipient background of 20% w/v sucrose and 186 5mM sodium citrate was evaluated over 2 weeks of storage at -80°C, -20°C, 2-8°C, 25°C, and 40°C and 187 compared to freshly prepared controls. Vaccine formulation particle size (70-100 nm) was maintained 188 over the 2-week period at all storage temperatures (Supplemental Figure S2A ). The vaccine also retained 189 its ability to induce SARS-CoV-2-specific serum IgG in C57BL/6 mice as measured by ELISA after storage 190 at all temperatures except 40°C (Supplemental Figure S2B ) and showed a trend towards potentially 191 reduced potency developing in the 25°C-stored vaccine after 2 weeks. 192

In order to achieve long-term storage stability, we lyophilized the AAHI-SC2 vaccine and 193 characterized it before and after storage at various temperatures compared to the frozen liquid vaccine. 194

Previously, we demonstrated proof of concept for the long-term storage stability of this platform using 195 SEAP reporter saRNA in the presence of 20% w/v sucrose as a lyoprotectant with a background of 2mM 196 sodium citrate. 34 Here, the AAHI-SC2 vaccine was lyophilized under those same conditions in addition to 197 two alternative excipient backgrounds: 20% sucrose with 5mM sodium citrate (increasing the 198 concentration of sodium citrate, a metal chelator) and 20% sucrose with 1mM sodium citrate and 10mM 199 Tris (increasing the pH of the system with addition of Tris buffer). Data with the alternative excipient 200 backgrounds are presented in Supplemental Figure S3 ; however, the original proof-of-concept excipient 201 formulation performed the best ( Figure 6) . 202

Vaccine at each excipient condition was stored frozen at -80°C or lyophilized at 4°C, 25°C, or 203 40°C. A freshly complexed positive control was also prepared at each timepoint for comparison. For the 204 proof-of-concept excipient formulation, vaccine particle size increased by approximately 30 nm 205 immediately after lyophilization, but after that initial increase, particle size was maintained over the 6 206 months of the study ( Figure 6A ). RNA integrity was also maintained after lyophilization and throughout 6 207 months of storage under frozen conditions and lyophilized conditions stored at 4°C and 25°C ( Figure 6B ). 208

The accelerated storage condition of 40°C was eliminated from the stability study after 3 months due to 209 complete degradation of the RNA (data not shown). 210

Vaccine immunogenicity during storage was assessed by injecting stored vaccine intramuscularly 211 into 6-8 week old C57BL/6J mice (5 mice per storage condition per timepoint), collecting mouse serum 212 samples 14 days post-immunization, and testing these sera for SARS-CoV-2 spike protein-binding 213 antibodies by ELISA, as described above. The ability of each stored vaccine to induce an immune 214 response in vivo was predicted well by the presence of a major intact RNA band by agarose gel 215 electrophoresis. As expected, the -80°C-frozen vaccine maintained the ability to induce SARS-CoV-2-216 specific IgG throughout the 6-month stability study ( Figure 6C ) along with equivalent pseudovirus 217 neutralization titers to freshly complexed vaccine at each timepoint (p > 0.05) ( Figure 6D ). After storage 218 at 40°C for 3 months, both antibody titers and neutralizing titers were diminished with lyophilized 219 vaccine ( Figure 6C -D), as expected for this accelerated degradation condition. 220

The lyophilized vaccine stored at 4°C or at 25°C continued to elicit robust serum SARS-CoV-2-221 specific-IgG titers after 6 months of storage ( Figure 6C ). The lyophilized 4°C-stored vaccine maintained 222 its ability to stimulate mouse serum IgG over the course of the study, comparable to the lyophilized 223 vaccine prior to storage; although after 6 months the SARS-CoV-2-specific IgG titer induced by the 4°C-224 stored vaccine was lower than that induced by the freshly complexed control at that timepoint (p < 225 0.05). The 25°C-stored vaccine after 3 months of storage induced a decreased mouse serum IgG titer 226 relative to both the lyophilized vaccine prior to storage and the freshly complexed vaccine at each 227 timepoint (p < 0.05). Despite this apparent decrease in total spike-binding IgG, lyophilized vaccine 228 induced equivalent serum pseudovirus neutralization titers relative to fresh-mixed vaccine or lyophilized 229 vaccine prior to storage, with no significant differences observed between neutralizing antibody titers 230 induced by 4°C-and 25°C-stored lyophilized samples relative to those induced by freshly mixed vaccine 231 at each timepoint or relative to those induced by the lyophilized sample prior to storage (p > 0.05) 232 ( Figure 6D ). This suggests the long-term retention of lyophilized vaccine immunogenicity after storage at 233 refrigerated or even ambient temperatures. 234

AAHI-SC2, combining the potency and self-adjuvanting nature of saRNA with the improved stability and 237 immune-stimulating properties of the NLC formulation, exhibits many characteristics of a "next-238 generation" SARS-CoV-2 RNA vaccine. Immunization of mice with AAHI-SC2 induces cross-variant 239 neutralizing antibodies, establishes key long-lived bone marrow-resident antibody secreting cell 240 populations, and generates robust Th1-biased polyfunctional T cell responses. AAHI-SC2 exhibits 241 enhanced thermostability, allowing it to be stored at room temperature or refrigerated conditions for at 242 least 6 months-and possibly far longer-while still maintaining the ability to stimulate equivalent 243 neutralizing antibody titers. This vaccine, soon to begin human testing in accelerated Phase I/II clinical 244 trials, demonstrates excellent preclinical immunogenicity, with far simpler manufacturing and cold-chain 245 requirements than mRNA vaccines currently in use, enabling greater global vaccine access and 246 distribution. 247

The two mRNA vaccines in widespread use rely on LNP-encapsulated nucleoside-modified RNA, 248 and both are thought to be effective via induction of neutralizing antibody titers. 41,42 Our vaccine elicited 249 neutralizing antibody responses in mice that well exceeded levels that have been predicted to be 250 protective. 43 Direct comparisons of our saRNA/NLC vaccine to the approved mRNA vaccines were not 251 possible in this study; however, literature comparisons suggest that, acknowledging minor differences in 252 the immunogenicity assays used, AAHI-SC2 humoral immunogenicity in C57BL/6J mice likely compares 253 favorably with these mRNA vaccines. 6,7 254

While some studies indicate that neutralizing antibody titers may be considered correlates of 255 protection, 44-48 T cell responses have been shown to be critical for the control and clearance of infection, 256 as well as for mediating protection against emerging variants and preserving long-term immunity. 48-51 T 257 cell responses appear earlier than neutralizing antibodies following vaccination, 52 and the timing of their 258 appearance correlates with the attainment of vaccine protective efficacy. 3 Although emerging variants 259 13 of SARS-CoV-2 appear to be able to evade vaccine-induced humoral immune responses, 53,54 T cell 260 immunity appears to be more durable in response to these variants 55,56 likely because T cell epitopes are 261 more highly conserved in emergent SARS-CoV-2 variants than the corresponding B cell epitopes. 56 In addition to its immunogenicity, thermostability of the AAHI-SC2 vaccine is critical for its 283 potential utility. Several components of mRNA vaccines may affect their stability during storage: LNP 284 formulation, modified nucleosides, GC content, RNA length, and non-coding regions. 24, 25 While 285 optimization of these properties has led to improved mRNA stability, stringent cold-chain requirements 286 are still necessary for the Moderna and Pfizer-BioNTech vaccines. 9,10 These requirements were a 287 monumental challenge in the early days of vaccine rollout and continue to be a major impediment to 288 worldwide distribution, 66 particularly given the short stability window of the Moderna and Pfizer-289

BioNTech vaccines at room temperature (20-25°C). 290

Additional RNA vaccines are currently under development with reported stability data, but these 291 data are sparse and indicate limited, short-term room-temperature stability of days to a few weeks at 292 best. 40,58,67 As these reports illustrate, maintenance of RNA integrity during storage and after 293 administration is challenging. RNA molecules are more susceptible to degradation than DNA due to the 294 presence of the 2' hydroxyl group on the ribose backbone. RNAs must also be protected from 295 degradation by ubiquitous ribonucleases. Lyophilization is a known strategy to stabilize RNA by itself for 296 long-term storage; 68 however, limited stability has been demonstrated for lyophilized RNA vaccines 297 encapsulated in LNPs. 12, 13 The complex structure of LNPs may make lyophilization difficult due to the 298 potential for rupture of the lipid layers and/or payload leakage, particularly important due to the 299 encapsulation of the RNA. In contrast, the NLC delivery vehicle, which has a structure more similar to an 300 oil-in-water emulsion than an LNP, has previously demonstrated stability upon lyophilization. 34 In this 301 work, demonstrating at least 6 months of stability at ambient temperature, the AAHI-SC2 vaccine 302 represents a potential major improvement in RNA vaccine stability and distribution. 303

Besides its thermostability profile, AAHI-SC2 also offers several manufacturing and supply-chain 304 advantages relative to existing vaccines and vaccine candidates. NLC manufacturing relies on equipment 305 already utilized in standard oil-in-water emulsion-based vaccine adjuvant production and materials that 306 can be sourced from multiple different commercial vendors. In contrast to LNPs, which require 307 encapsulation of the RNA during production, our vaccine technology allows for the NLC and RNA to be 308 produced separately and complexed by simple mixing at any point up to just before administration. This 309 approach greatly simplifies manufacturing, enables stockpiling of NLC for pandemic preparedness, 34 and 310 allows for post-manufacturing substitution of saRNA species to address emerging viruses or viral 311 variants of concern. The AAHI-SC2 vaccine also does not contain pseudouridine components or highly 312 specialized proprietary lipids whose scarcity and proprietary nature present challenges for sourcing. 17 313

We present a highly potent SARS-CoV-2 saRNA vaccine that induces strong immune responses in mice 315 and demonstrates establishment of long-lived antibody-secreting plasma cell populations. The potency 316 of this vaccine in conjunction with its induction of broadly cross-variant neutralizing antibodies may 317 allow this vaccine to provide effective protection against many SARS-CoV-2 strains. While this vaccine 318 candidate is only now advancing into non-human primate studies, animal efficacy testing, and human 319 trials, we believe it represents an important advance in RNA vaccine technology, particularly for rural 320 areas and the developing world. A key advantage of this technology is its improved manufacturability 321 and thermostability relative to other mRNA vaccines, enabling lower costs and widespread distribution 322 in lower income countries without the need for an extreme cold chain. This vaccine is scheduled to 323 advance into efficacy studies in non-human primates and an accelerated Phase I/II clinical trial. This 324 thermostable saRNA/NLC vaccine technology is valuable not just for the current SARS-CoV-2 pandemic 325 but also for future pandemic preparedness and responsiveness. Ludwigshafen, Germany) were mixed and heated at 60°C in a bath sonicator to create the oil phase. 364

Polysorbate 80 (MilliporeSigma, Burlington, MA) was separately diluted in 10mM sodium citrate 365 trihydrate and heated to 60°C in a bath sonicator to create the aqueous phase. After dispersion of 366 components in each phase, a high-shear mixer (Silverson Machines, East Longmeadow, MA) was used at 367 ~5,000 rpm to mix the oil and aqueous phases. Particle size of the mixture was then further decreased 368 by high-pressure homogenization by processing at 30,000 psi for ten discrete passes using an M110P 369 Microfluidizer (Microfluidics, Westwood, MA). The NLC product was then filtered through a 0.22 µm PES 370 filter and stored at 2°C-8°C until use. 371

18 Vaccine complexes for immediate in vivo injection were created by mixing aqueous RNA 1:1 by volume 373 with NLC diluted in a buffer containing 10mM sodium citrate and 20% w/v sucrose. All vaccines were 374 prepared at a nitrogen:phosphate (N:P) ratio of 15, representing the ratio of amine groups on the NLC 375 DOTAP to phosphate groups on the RNA backbone. This produced a vaccine solution containing the 376 intended dose of complexed saRNA/NLC in an isotonic 10% w/v sucrose, 5mM sodium citrate solution. 377

Vaccine was incubated on ice for 30 minutes after mixing to ensure complete complexing. 378

Hydrodynamic diameter (particle size) of the NLC and vaccine nanoparticles was determined 379 using dynamic light scattering (Zetasizer Nano ZS, Malvern Panalytical, Malvern, UK) on triplicate 1:100 380 dilutions in nuclease-free water. Sizing was done in a disposable polystyrene cuvette using previously 381 established parameters. 34 382

Free and complexed RNA integrity and NLC-provided protection against RNases were evaluated 383 by visualizing RNA integrity after agarose gel electrophoresis. RNA samples were diluted to 40 ng/μL 384 RNA in nuclease-free water. For RNase treatment, this diluted RNA was incubated with RNase A (10 385 mg/mL, Thermo Scientific, Waltham, MA) at a mass ratio of 1:500 RNase:RNA for 30 minutes at room 386 temperature, followed by incubation with proteinase K (~20 mg/mL, Thermo Scientific) at a mass ratio 387 of 1:100 RNase A:proteinase K for 10 minutes at 55°C. For complexed samples, RNA was extracted from 388 complexes prior to gel electrophoresis by phenol:chloroform extraction. All RNA samples were mixed 389 with glyoxal loading dye (Invitrogen, Waltham, MA) 1:1 by volume, incubated at 50°C for 20 minutes, 390 loaded on a denatured 1% agarose gel in NorthernMax-Gly running buffer (Invitrogen) alongside 391

Millennium RNA Markers (Thermo Fisher Scientific), and run at 120 V for 45 minutes before imaging on a 392

ChemiDoc MP Imaging System (Bio-Rad Laboratories, Hercules, CA). 393

Vaccine complexes intended for lyophilization and storage were prepared similarly to above by mixing 395 aqueous RNA 1:1 by volume with NLC diluted in either 20% w/v sucrose only, 20% w/v sucrose and 5mM 396 sodium citrate, or 20% w/v sucrose with both 1mM sodium citrate and 10mM Tris. All vaccines with all 397 excipient conditions were prepared at an N:P ratio of 15 and were incubated on ice for 30 minutes after 398 mixing to ensure complete complexing. After complexing, vaccine was lyophilized using a VirTis 399 saline (PBS) and incubated overnight at 4°C. The coating solution was removed, and blocking buffer (2% 420 dry milk, 0.05% Tween 20, and 1% goat serum) was applied for at least 1 hour. On a separate, low-421 binding plate, each sample was diluted 1:40 and then serially 1:2 to create a 14-point dilution curve for 422 each sample. Naïve mouse serum, used as the negative control, was diluted identically to the samples. A 423 SARS-CoV-2 neutralizing monoclonal antibody (mAb; GenScript, Piscataway, NJ; #A02057), was used as a 424 positive control at a known starting concentration of 3.2 ng/µL followed by serial 1:2 dilutions similarly 425 to each sample and negative control. SARS-CoV-2 spike protein-coated and blocked assay plates were 426 washed, and serially diluted samples were then transferred onto the coated plates followed by a 1-hour 427 incubation. Plates were then washed, and spike protein-bound antibodies were detected using an Anti-428

Mouse IgG (Fc Specific)-Alkaline Phosphatase antibody (Sigma-Aldrich, #A2429) at a 1:4000 dilution in 429 blocking buffer. Plates were washed and then developed using phosphatase substrate (Sigma-Aldrich, 430 #S0942) tablets dissolved in diethanolamine substrate buffer (Fisher Scientific, Waltham, MA; #PI34064) 431 at a final concentration of 1 mg/mL. After a 30-minute development, plates were read 432 spectrophotometrically at 405 nm. A 4-point logistic curve (4PL) was used to fit the antibody standard 433 titration curve. Sample concentrations were interpolated off the linear region of each sample dilution 434 curve using the standard curve for absolute quantification of antibody titers. For Supplemental Figure S2  435 only, antibody level was quantified by endpoint titer, with the endpoint titer defined as the dilution at 436 which each sample dilution curve rises to above 3 standard deviations above assay background. 437

For IgG1 and IgG2a isotype-specific ELISAs, the identical plate coating and blocking procedures 438 were conducted. For the IgG1 assay, the standard curve was run using an IgG1 SARS-CoV-2 neutralizing 439 antibody (GenScript) for full quantification. Sample dilution and incubation were identical to the total 440 IgG curve, and plates were probed with IgG1-and IgG2a-specific secondary alkaline phosphatase-441 conjugated detection antibodies prior to development, reading, and quantification as described above. 442

The SARS-CoV-2 pseudovirus neutralizing antibody titers of immunized mouse sera were measured by 444 pseudovirus neutralization assays using procedures adapted from Crawford et al. 70 Lentiviral SARS-CoV-2 445 spike protein pseudotyped particles were prepared by following the Bioland Scientific (Paramount, CA) 446

BioT plasmid transfection protocol. Briefly, HEK-293 cells (American Type Culture Collection, Manassas, 447 VA; #CRL-3216) were plated at 4 x 10 5 cells/mL in 6-well plates 18-24 hours before the assay to achieve 448 50-70% confluency at assay start. Cellular growth medium was then replaced with serum-free Gibco Thomas Peacock, Imperial College London, UK). BioT transfection reagent (Bioland Scientific) was used 456 to mediate the co-transfection. The assay plates were incubated for 24 hours at standard cell culture 457 conditions (37°C and 5% CO2). Then the serum-free media was aspirated off, and fresh growth medium 458 (Gibco DMEM with GlutaMAX and 10% fetal bovine serum [FBS] ) was added to the plates before 459 returning them to the incubator for an additional 48 hours. Pseudovirus stocks were collected by 460 harvesting the supernatants from the plates, filtering them through a 0.2 μm PES filter (Thermo 461 Scientific), and freezing at -80 o C until titration and use.

Mouse serum samples were diluted 1:10 in medium (Gibco DMEM with GlutaMAX and 10% FBS) 463 and then serially diluted 1:2 for 11 total dilutions in 96-well V-bottom plates. Polybrene (Sigma-Aldrich) 464 was then added at a concentration of 5 µg/mL to every well on the plate, and pseudovirus, diluted to a 465 titer of 1 x 10 8 total integrated intensity units/mL as per titers determined independently for each 466 pseudovirus batch, was added 1:1 to the diluted serum samples. The plates were incubated for 1 hour at 467 37°C and 5% CO2. Serum-virus mix was then added in duplicate to Human Angiotensin-Converting 468 Neutralization data for each sample were fit with a four-parameter sigmoidal curve that was used to 474 interpolate IC50 values. 475 A Wuhan-strain pseudoneutralization test using the World Health Organization (WHO) standard 476 for neutralization assays with an official IC50 of 1000 resulted in an IC50 of 7800 using our assay, 477 suggesting that our test is more sensitive than the WHO assay but may overreport IC50 values-by less 478 than one log10-an effect likely most pronounced for strongly neutralizing samples. 479

Spleens were dissociated in 4 mL of RPMI medium by manual maceration through a cell strainer using 481 the end of a syringe plunger. Homogenized samples were centrifuged at 400 x g for 5 minutes to pellet 482 red blood cells. The supernatants containing lymphocytes were transferred to 5-mL mesh-cap tubes to 483 strain out any remaining tissue debris or were lysed with ammonium-chloride-potassium (ACK) buffer 484 and washed. Cell counts for each sample were obtained on a Guava easyCyte (Luminex, Austin, TX). Each 485 spleen sample was seeded in 96-well round-bottom plates at 1-2 x 10 6 cells per well in RPMI medium 486 containing 10% FBS, 50μM beta-mercaptoethanol, CD28 costimulatory antibody, and brefeldin A. Cells 487 were stimulated with one of three stimulation treatments: 0.0475% dimethyl sulphoxide (DMSO) as a 488 negative stimulation control, 10 μg/well (1 μg/mL) of spike peptide pool (JPT Peptide Technologies, 489 Berlin, Germany; #PM-WCPV-S-1) in an equivalent amount of DMSO , or 10 μg/well of phorbol myristate 490 acetate (PMA)/ionomycin solution. After 6 hours of incubation at 37°C with 5% CO2, plates were 491 centrifuged at 400 x g for 3 minutes, the supernatants were removed by pipetting, and cells were 492 resuspended in PBS. Plates were centrifuged, the supernatants were removed, and cells were stained 493 for flow cytometry. Splenocytes were stained for viability with Zombie Green (BioLegend, San Diego, CA) 494 in 50 μL of PBS, and then Fc receptors were blocked with CD16/CD32 antibody (Invitrogen). Cells were 495 then surface stained with fluorochrome-labeled mAbs specific for mouse CD4, CD8, CD44, and CD107a 496 in 50 μL of staining buffer (PBS with 0.5% bovine serum albumin and 0.1% sodium azide). Cells were 497 washed twice, permeabilized using the Fixation/Permeabilization Kit (BD Biosciences, Franklin Lakes, NJ), 498 and stained with fluorochrome-labeled mAbs specific for mouse TNFα, IL-2, IFNγ, IL-5, IL-10, and IL-17A. 499

After two washes in staining buffer, cells were resuspended in 100 μL of staining buffer and analyzed on 500 an LSRFortessa flow cytometer (BD Biosciences). After initial gating for live CD4 + or CD8 + lymphocytes, 501 cells were gated for cytokine positivity. Quality of the response was determined by gating on cells that 502 were double or triple positive for these markers. Cells triple positive for TNFα, IL-2, and IFNγ were 503 considered activated polyfunctional T cells. 504

ELISpot plates (MilliporeSigma) were coated with either IFNγ (BD Biosciences, #51-2525KZ), IL-17A 506 (Invitrogen, #88-7371-88), or IL-5 (BD Biosciences, #51-1805KZ) capture antibodies at a 1:200 dilution in 507

ELISpot coating buffer (eBioscience, Waltham, MA). After an overnight incubation at 4 o C, plates were 508 washed and then blocked with complete RPMI (cRPMI) medium for at least 2 hours. Splenocytes 509 24 harvested as described above were plated at 2 x 10 5 cells per well. A subset of each sample was 510 stimulated with PepMix SARS-CoV-2 (JPT Peptide Technologies, #PM-WCPV-S-1) at a final concentration 511 of 1 µg/mL. Plates were then incubated at 37°C and 5% CO2 for 48 hours. After a wash with PBS with 512 0.1% Tween 20, 100 µL of detection antibody (IFNγ, BD Biosciences, #51-1818KA; IL-17A, Invitrogen, 513 #88-7371-88; and IL-5, BD Biosciences, #51-1806KZ) was added at a 1:250 dilution in ELISpot diluent 514 (eBioscience) overnight at 4 o C. Plates were washed and developed with Vector NovaRED Substrate 515

Peroxidase (Vector Laboratories, Burlingame, CA; #SK-4800) for 15 minutes. The reaction was stopped 516 by washing the plates with deionized water, and plates were left to dry in the dark. Spots were counted 517 and data were analyzed using ImmunoSpot software (Cellular Technology Limited, Cleveland, OH). 518

Presence of antibody-secreting bone marrow-resident cells were measured by ELISpot. MultiScreen IP 520

Filter plates (0.45 µm, MilliporeSigma) were treated with 15 µL of 35% ethanol for 30 seconds. After a 521 wash with PBS, plates were coated with 100 µL of Recombinant SARS-CoV-2 Spike His Protein, Carrier 522

Free, (R&D Systems, #10549-CV-100) at a concentration of 2 µg/mL diluted in ELISpot coating buffer 523 (eBioScience). Plates were incubated overnight at 4°C, washed with PBS with 0.1% Tween 20, and 524 blocked with cRPMI medium for at least 2 hours. 525

To prepare bone marrow, both femurs were removed from each mouse and inserted into a 526 snipped-end 0.6 mL tube (Eppendorf, Hamburg, Germany) inserted into a 1.5 mL Eppendorf tube 527 containing 1 mL of cRPMI medium. Femurs were centrifuged for 15 seconds at 10,000 rpm, and 528 supernatant was discarded. The cell pellets were briefly vortexed and resuspended in 200 µg of RBC lysis 529 buffer (Invitrogen), and they were incubated on ice for 30 seconds. After addition of 800 μL of cRPMI 530 medium, cells were centrifuged 5 minutes at 400 x g, and supernatant was decanted. Cells were 531 25 resuspended in 1 mL of cRPMI medium, counted, and transferred to prepared filter plates described 532 above at 1 million cells per well followed by a 3-fold dilution across five adjacent wells. 533

After a 3-hour incubation, plates were washed with PBS with 0.1% Tween 20, and secondary 534 antibody (Goat Anti-Mouse IgG-HRP or IgA-HRP [SouthernBiotech, Birmingham, AL; #1030-05 and 535 #1040-05]) was added at a 1:1000 dilution in PBS with 0.1% Tween and 5% FBS overnight at 4 o C. Plates 536 were then washed three times in PBS with 0.1% Tween 20 and two times in PBS. For development, 100 537 µL of Vector NovaRED Substrate Peroxidase (Vector Laboratories, #SK-4800) was applied for 7 minutes. 538

The reaction was stopped by rinsing plates with distilled water for 2 minutes, and plates were dried in 539 the dark. Spots were counted and data were analyzed using ImmunoSpot software (Cellular Technology 540 Limited). 541

Log-normalized pseudovirus variant neutralization was compared using mixed effects analysis with 543 multiple comparison correction. SARS-CoV-2-specific IgG levels in mouse sera by stored vaccines were 544 analyzed on log-transformed data by one-way ANOVA at each timepoint followed by Dunnett's multiple 545 comparison test comparing each stored sample to the freshly complexed positive control at each 546 timepoint. All statistical analyses were conducted using Prism 9 (GraphPad Software, San Diego, CA). 547

We would like to thank Jesse Bloom (Fred Hutchinson Cancer Research Center) and Thomas Peacock 549 (Imperial College London) for sharing the SARS-CoV-2 spike protein plasmids used for pseudovirus 550 production. We are additionally grateful to Elise Larson, who conducted the manufacture of the NLC 551 used in these studies; Richard Cabullos, who manufactured some RNA products used in this study; and 552

Jeff Guderian. John Tite provided valuable technical input. We also thank Theresa Britschgi, who was 553 instrumental as project manager for this work; Valerie Soza, for editorial assistance; and Cassandra 554 Baden, for graphic design. 555 This work was funded in whole or in part with funds from Amyris, Inc., and ImmunityBio, Inc. 556

The content is solely the responsibility of the authors and does not necessarily represent the views of 557 the funders. 558 Laczko, D., Hogan, M.J., Toulmin, S.A., Hicks, P., Lederer, K., Gaudette, B.T., Castano, D., Amanat, 595 F., Muramatsu, H., Oguin, T.H., 3rd, Ojha, A., et al. (2020) . A single immunization with 596 nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses 597 against SARS-CoV-2 in mice. Immunity 53, 724-732 e727. 10.1016/j.immuni.2020.07.019. 598

An interactive web-based dashboard to track COVID-19

A global database of COVID-19 vaccinations

Safety and efficacy of the BNT162b2

mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273

SARS-CoV-2 vaccine

Priorities for the COVID-600 19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission

Spikevax (previously COVID-19 vaccine Moderna): European 603 public assessment report (EPAR) -Product information

mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability

Long-term storage 610 of lipid-like nanoparticles for mRNA delivery

Achieving long-term stability of lipid 613 nanoparticles: examining the effect of pH, temperature, and lyophilization

Addressing the cold reality of mRNA vaccine stability

The COVID-19 vaccine race: 622 challenges and opportunities in vaccine formulation

COVID-19 vaccine development during pandemic: gap analysis, opportunities, 625 and impact on future emerging infectious disease development strategies

Resurgence of SARS-CoV-2 infection in a highly vaccinated health system 629 workforce

Primary, recall, and decay kinetics 632 of SARS-CoV-2 vaccine antibody responses

mRNA COVID-19 vaccines and long-lived plasma cells: a 635 complicated relationship. Vaccines (Basel) 9

The fight to manufacture COVID vaccines in lower-income countries

mRNA vaccines -a new era in 639 vaccinology

Delivering the messenger: 641 advances in technologies for therapeutic mRNA delivery

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

A single dose of self-transcribing and 649 replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice

An alphavirus-derived replicon 653 RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and 654 nonhuman primates

A self-amplifying mRNA COVID-657 19 vaccine drives potent and broad immune responses at low doses that protects non-human 658 primates against SARS-CoV-2. bioRxiv

An alphavirus 661 replicon-based vaccine expressing a stabilized spike antigen induces protective immunity and 662 prevents transmission of SARS-CoV-2 between cats

The evaluation of novel oral vaccines 665 based on self-amplifying RNA lipid nanparticles (saRNA LNPs), saRNA transfected Lactobacillus 666 plantarum LNPs, and saRNA transfected Lactobacillus plantarum to neutralize SARS-CoV-2 667 variants alpha and delta

The oral vaccine based on self-669 replicating RNA lipid nanoparticles can simultaneously neutralize both SARS-CoV-2 variants 670 alpha and delta

Safety and immunogenicity of a self-673 amplifying RNA vaccine against COVID-19: COVAC1, a Phase I, dose-ranging trial

A Phase 1/2 randomized, double-blinded, 677 placebo controlled ascending dose trial to assess the safety

ARCT-021 in healthy adults. medRxiv

A nanostructured lipid carrier for delivery of 682 a replicating viral RNA provides single, low-dose protection against Zika

A flexible, thermostable nanostructured lipid carrier platform for RNA 686 vaccine delivery

Structural and functional analysis of 690 the D614G SARS-CoV-2 spike protein variant

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Immunogenicity and structures of a 697 rationally designed prefusion MERS-CoV spike antigen

Structural analysis of full-length

SARS-CoV-2 spike protein from an advanced vaccine candidate

Live-attenuated

RNA hybrid vaccine technology provides single-dose protection against Chikungunya virus

Intramuscular delivery of replicon RNA 708 encoding ZIKV-117 human monoclonal antibody protects against Zika virus infection

An 712 mRNA vaccine against SARS-CoV-2 -preliminary report

Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

COVID-19 vaccine mRNA-1273 elicits 720 a protective immune profile in mice that is not associated with vaccine-enhanced disease upon

SARS-CoV-2 challenge

Neutralizing antibody levels are highly predictive 727 of immune protection from symptomatic SARS-CoV-2 infection

Correlates of protection against symptomatic and 731 asymptomatic SARS-CoV-2 infection

Immune correlates 735 analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Correlates of protection against SARS-CoV-2 in 739 rhesus macaques

CD8 + T cells contribute to survival in 744 patients with COVID-19 and hematologic cancer

SARS-CoV-2 responsive T cell 748 numbers and anti-spike IgG levels are both associated with protection from COVID-19: a 749 prospective cohort study in keyworkers. medRxiv

Early T cell and binding antibody responses are 753 associated with COVID-19 RNA vaccine efficacy onset

SARS-CoV-2 Omicron has extensive but 757 incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

Effectiveness of Covid-19 vaccines 761 against the B.1.617.2 (delta) variant

SARS-CoV-2 variants of 765 concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and 766 vaccine recipients

Dynamics of antibody response to

BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional

Novel lipid nanoparticle provides potent

SARS-CoV-2 mRNA vaccine at low dose with low local reactogenicity, high thermostability and 778 limited systemic biodistribution

Rapid COVID-19 vaccine development

Developing Covid-19 vaccines at 783 pandemic speed

Vaccine-associated 786 enhanced disease: case definition and guidelines for data collection, analysis, and presentation 787 of immunization safety data

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute 791 respiratory distress syndrome

Targets of T cell responses 794 to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Antibody-dependent SARS coronavirus infection is 798 mediated by antibodies against spike proteins

Antibody-dependent enhancement of SARS-CoV-2 infection is mediated by the IgG receptors

FcgammaRIIA and FcgammaRIIIA but does not contribute to aberrant cytokine production by 803 macrophages

Introducing new vaccines in 805 low-and middle-income countries: challenges and approaches

A thermostable mRNA vaccine against COVID-19

Committee for the Update of the Guide for the Care and Use of Laboratory Animals

Guide for the Care and Use of Laboratory Animals

Protocol and reagents for 817 pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays

conducted on log-transformed data by one-way ANOVA at each timepoint, comparing each stored 875 vaccine preparation to freshly complexed vaccine with multiple comparison corrections. *p < 0.05, **p < 876 0.01, ****p < 0.0001. D) Pseudovirus neutralization titers induced in female C57BL/6J mice by the 877 vaccine after storage under the indicated conditions for the indicated times. LOD = limit of detection. n = 878